- STAT+: Biogen Alzheimer’s drug slowed decline at rates on par with approved therapies, study showsAn experimental Alzheimer's drug from Biogen, one with a novel approach, slowed decline at comparable rates as approved drugs in a mid-stage study.STAT · 14d ago↗ source
- Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugsThe study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.BioPharma Dive · 14d ago↗ source
- Draig nets $65M to advance depression drug aimed at rebuilding synapsesDraig Therapeutics has secured $65 million in an oversubscribed Series B raise to advance a pipeline of neuropsychiatry drugs, including its lead depression program designed to modulate the AMPA re…